Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid and Accurate Confirmatory Diagnosis of HTLV-1/2 Infection.

Tytuł:
Loop-Mediated Isothermal Amplification (LAMP) Assay for Rapid and Accurate Confirmatory Diagnosis of HTLV-1/2 Infection.
Autorzy:
Gomes Y; Laboratory for Clinical Research in Neuroinfections, Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.
Caterino-de-Araujo A; Laboratory of HTLV Research, Immunology Center, Adolfo Lutz Institute, São Paulo 01246-000, Brazil.
Campos K; Laboratory of HTLV Research, Immunology Center, Adolfo Lutz Institute, São Paulo 01246-000, Brazil.
Gonçalves MG; Laboratory of HTLV Research, Immunology Center, Adolfo Lutz Institute, São Paulo 01246-000, Brazil.
Leite AC; Laboratory for Clinical Research in Neuroinfections, Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.
Lima MA; Laboratory for Clinical Research in Neuroinfections, Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.
Araújo A; Laboratory for Clinical Research in Neuroinfections, Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.
Silva MT; Laboratory for Clinical Research in Neuroinfections, Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.
Espíndola O; Laboratory for Clinical Research in Neuroinfections, Evandro Chagas National Institute of Infectious Diseases (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-900, Brazil.
Źródło:
Viruses [Viruses] 2020 Sep 04; Vol. 12 (9). Date of Electronic Publication: 2020 Sep 04.
Typ publikacji:
Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI
MeSH Terms:
HTLV-I Infections/*virology
HTLV-II Infections/*virology
Human T-lymphotropic virus 1/*genetics
Human T-lymphotropic virus 2/*genetics
Molecular Diagnostic Techniques/*methods
Nucleic Acid Amplification Techniques/*methods
Blood/virology ; Clinical Laboratory Techniques ; HTLV-I Infections/blood ; HTLV-I Infections/diagnosis ; HTLV-II Infections/blood ; HTLV-II Infections/diagnosis ; Human T-lymphotropic virus 1/classification ; Human T-lymphotropic virus 1/isolation & purification ; Human T-lymphotropic virus 2/classification ; Human T-lymphotropic virus 2/isolation & purification ; Humans ; Sensitivity and Specificity
References:
Analyst. 2018 Apr 16;143(8):1924-1933. (PMID: 29620773)
Expert Rev Clin Immunol. 2014 Nov;10(11):1531-46. (PMID: 25340428)
Clin Microbiol Infect. 2011 Feb;17(2):210-3. (PMID: 20298270)
J Med Virol. 2010 Oct;82(10):1746-53. (PMID: 20827773)
J Med Virol. 2010 May;82(5):837-42. (PMID: 20336719)
Blood. 2017 Mar 2;129(9):1071-1081. (PMID: 28115366)
F1000Res. 2019 Feb 28;8:. (PMID: 30854194)
Virology. 1993 Sep;196(1):25-33. (PMID: 8356797)
Virol J. 2013 Sep 11;10:282. (PMID: 24025129)
J Clin Microbiol. 2017 Sep;55(9):2838-2849. (PMID: 28701419)
AIDS Rev. 2019;21(4):211-217. (PMID: 31834313)
Nucleic Acids Res. 2000 Jun 15;28(12):E63. (PMID: 10871386)
J Virol Methods. 2016 Dec;238:86-93. (PMID: 27793644)
AIDS Res Hum Retroviruses. 2006 Oct;22(10):953-9. (PMID: 17067264)
PLoS Negl Trop Dis. 2013 Nov 07;7(11):e2546. (PMID: 24244779)
AIDS Res Hum Retroviruses. 2014 Sep;30(9):907-11. (PMID: 24866083)
J Infect Dis. 2014 Feb 15;209(4):523-31. (PMID: 24068702)
FEMS Immunol Med Microbiol. 2011 Oct;63(1):144-7. (PMID: 21635570)
J Clin Microbiol. 2018 Nov 27;56(12):. (PMID: 30232131)
J Med Virol. 1994 Sep;44(1):104-9. (PMID: 7798879)
BMC Public Health. 2016 Aug 15;16:787. (PMID: 27526923)
J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S204-14. (PMID: 8797725)
Front Microbiol. 2012 Nov 15;3:388. (PMID: 23162541)
J Clin Virol. 2004 Dec;31(4):275-82. (PMID: 15494269)
J Clin Microbiol. 2019 Dec 23;58(1):. (PMID: 31597749)
Am J Trop Med Hyg. 2006 Feb;74(2):246-9. (PMID: 16474078)
BMC Infect Dis. 2019 May 22;19(1):459. (PMID: 31117977)
Emerg Microbes Infect. 2020 Dec;9(1):998-1007. (PMID: 32306853)
Front Microbiol. 2019 Oct 15;10:2234. (PMID: 31681184)
J Virol Methods. 2011 May;173(2):280-6. (PMID: 21349293)
Transfusion. 2000 Aug;40(8):924-30. (PMID: 10960518)
Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7694-8. (PMID: 1881912)
Transfusion. 2002 Jun;42(6):780-91. (PMID: 12147033)
Cad Saude Publica. 2005 May-Jun;21(3):926-31. (PMID: 15868051)
Clin Infect Dis. 2013 Nov;57(10):1417-24. (PMID: 23956168)
J Clin Virol. 2008 Jun;42(2):149-55. (PMID: 18346935)
J Infect Dis. 1999 Sep;180(3):685-94. (PMID: 10438355)
J Clin Microbiol. 2010 Jun;48(6):2050-2. (PMID: 20351207)
PLoS Negl Trop Dis. 2013 Sep 26;7(9):e2418. (PMID: 24086779)
J Clin Microbiol. 2010 Mar;48(3):728-35. (PMID: 20071551)
AIDS Rev. 2009 Apr-Jun;11(2):71-8. (PMID: 19529747)
Transfus Clin Biol. 2016 Feb;23(1):13-9. (PMID: 26778839)
J Virol. 2010 Jul;84(14):7278-87. (PMID: 20463074)
Rev Inst Med Trop Sao Paulo. 2015 Jan-Feb;57(1):1-13. (PMID: 25651320)
Oncogene. 2005 Sep 5;24(39):6058-68. (PMID: 16155612)
J Infect Dis. 2011 May 1;203(9):1316-23. (PMID: 21459818)
Blood. 2011 Mar 17;117(11):3113-22. (PMID: 21228324)
Braz J Med Biol Res. 2005 Nov;38(11):1643-7. (PMID: 16258633)
PLoS Negl Trop Dis. 2017 Jan 6;11(1):e0005278. (PMID: 28060812)
Retrovirology. 2019 Dec 16;16(1):39. (PMID: 31842895)
J Exp Med. 1984 Apr 1;159(4):1105-16. (PMID: 6323614)
AIDS Res Hum Retroviruses. 2012 Feb;28(2):139-47. (PMID: 22171689)
J Med Virol. 2007 Feb;79(2):182-7. (PMID: 17177305)
Med J Aust. 2014 Jun 16;200(11):633-4. (PMID: 24938339)
Viruses. 2016 Jun 16;8(6):. (PMID: 27322309)
J Infect Dis. 1988 Dec;158(6):1193-7. (PMID: 3198935)
Tuberculosis (Edinb). 2018 Jan;108:35-40. (PMID: 29523325)
Viruses. 2015 Oct 28;7(11):5643-58. (PMID: 26516904)
J Infect Dis. 2007 Aug 15;196(4):510-21. (PMID: 17624835)
Braz J Infect Dis. 2017 May - Jun;21(3):297-305. (PMID: 28343818)
Rev Med Virol. 2008 Nov-Dec;18(6):407-21. (PMID: 18716992)
J Virol Methods. 2008 Aug;151(2):264-70. (PMID: 18524393)
Lancet Neurol. 2006 Dec;5(12):1068-76. (PMID: 17110288)
Rev Inst Med Trop Sao Paulo. 2007 Jul-Aug;49(4):225-30. (PMID: 17823751)
Mem Inst Oswaldo Cruz. 2018 Feb;113(2):130-134. (PMID: 29236927)
J Clin Virol. 2008 Apr;41(4):270-6. (PMID: 18296109)
Contributed Indexing:
Keywords: HTLV-1; HTLV-2; LAMP; confirmatory diagnosis
SCR Protocol:
LAMP assay
Entry Date(s):
Date Created: 20200909 Date Completed: 20210309 Latest Revision: 20210309
Update Code:
20240105
PubMed Central ID:
PMC7552020
DOI:
10.3390/v12090981
PMID:
32899621
Czasopismo naukowe
Laboratory diagnosis of human T-lymphotropic viruses (HTLV) 1 and 2 infection is performed by serological screening and further confirmation with serological or molecular assays. Thus, we developed a loop-mediated isothermal nucleic acid amplification (LAMP) assay for the detection of HTLV-1/2 in blood samples. The sensitivity and accuracy of HTLV-1/2 LAMP were defined with DNA samples from individuals infected with HTLV-1 ( n = 125), HTLV-2 ( n = 19), and coinfected with HIV ( n = 82), and compared with real-time polymerase chain reaction (qPCR) and PCR-restriction fragment length polymorphism (RFLP). The overall accuracy of HTLV-1/2 LAMP (95% CI 74.8-85.5%) was slightly superior to qPCR (95% CI 69.5-81.1%) and similar to PCR-RFLP (95% CI 79.5-89.3%). The sensitivity of LAMP was greater for HTLV-1 (95% CI 83.2-93.4%) than for HTLV-2 (95% CI 43.2-70.8%). This was also observed in qPCR and PCR-RFLP, which was associated with the commonly lower HTLV-2 proviral load. All molecular assays tested showed better results with samples from HTLV-1/2 mono-infected individuals compared with HIV-coinfected patients, who present lower CD4 T-cell counts. In conclusion, HTLV-1/2 LAMP had similar to superior performance than PCR-based assays, and therefore may represent an attractive alternative for HTLV-1/2 diagnosis due to reduced working time and costs, and the simple infrastructure needed.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies